Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
12/16/2011
Trade Name:
Maxalt and Maxalt-MLT
Generic or Proper Name (*):
rizatriptan
Indications Studied:
Treatment of migraine
Therapeutic Category:
Antimigraine
Ages Studied:
6-17 years
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Double-Blind/Placebo
No Patients:
977
No Centers:
191
No Countries:
57
BPCA(B), PREA(P):
B
Asian:
161
Black:
162
Other:
54
White:
597
Unknown:
0
Native Hawaiian or Pacific Islander:
1
American Indian/Alaska Native:
2
Hispanic/Latino:
94
Non-Hispanic/Non Latino:
608
-
-